BSX · 10-Q · 2026Q2 · Full report

Products and Technology

BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 23 · Surprise 24

Endoscopy growth was led by the biliary franchise, particularly the AXIOS™ Stent and Delivery System, along with the core GI franchise. Neuromodulation demand was driven by the Intracept™ Intraosseous Nerve Ablation System, Nalu Peripheral Nerve Stimulation System and deep brain stimulation products. Cardiovascular growth was led by the AGENT™ Drug-Coated Balloon and Farapulse™ Pulsed Field Ablation System, reflecting continued commercialization of less-invasive interventional technologies.

Key facts

• Endoscopy reported net sales growth in Q2 2026 was primarily driven by the biliary franchise led by the AXIOS™ Stent and Delivery System and the core GI franchise. source
• Neuromodulation reported net sales growth in Q2 and the first six months of 2026 was primarily driven by the comprehensive pain portfolio, led by the Intracept™ Intraosseous Nerve Ablation System and Nalu Peripheral Nerve Stimulation System, and the deep brain stimulation franchise. source